Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694810 · ClinicalTrials.gov registry record · Phase 1
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
A Phase 1 study of Acne Vulgaris, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01694810 is a Phase 1 study of Acne Vulgaris that has completed, run by Novan. The registered enrollment target is 60 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01694810, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess safety and tolerability of different doses of topical gel containing a new chemical entity, NVN1000, and the vehicle (gel without drug) applied to the face of healthy volunteers with high counts of Propionibacterium acnes. The test product will be applied once daily for 4 weeks. Exploratory measures include whether the topical product decreases the amount of a bacteria associated with acne (P. acnes).
Conditions Studied
Interventions
- DRUG 2% NVN1000 Topical Gel
- DRUG 4% NVN1000 Topical Gel
- DRUG 8% NVN1000 Topical Gel
- DRUG Vehicle Topical Gel
Study Locations (1)
Pennsylvania
- KGL, Inc - Broomall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694810
The ClinicalTrials.gov registry entry for NCT01694810 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (78% lower). The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 4 interventions - of which 2% NVN1000 Topical Gel is the first listed.
NCT01694810 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01694810 about?
NCT01694810 is a clinical study titled "Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers". The study will assess safety and tolerability of different doses of topical gel containing a new chemical entity, NVN1000, and the vehicle (gel without drug) applied to the face of healthy volunteers with high counts of Propionibacterium acnes. The test product will be applied once daily for 4 weeks...
What is the current status of trial NCT01694810?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-09. Estimated completion is 2012-11.
What conditions does trial NCT01694810 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01694810?
The interventions under investigation include: 2% NVN1000 Topical Gel (DRUG), 4% NVN1000 Topical Gel (DRUG), 8% NVN1000 Topical Gel (DRUG), Vehicle Topical Gel (DRUG).
Who is sponsoring clinical trial NCT01694810?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01694810 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.